Home » Newsletters » BioWorld Science

BioWorld Science

April 18, 2016

View Archived Issues

Cydan announces launch of orphan drug company Imara

Ganaxolone granted U.S. orphan drug desgination in status epilepticus

NewLink awarded DoD contract for filovirus vaccines

NICE recommends Translarna for Duchenne muscular dystrophy in England

Elorac acquires Gideon Pharmaceuticals

ABT-493 given with ABT-530 in MAGELLAN-I hepatitis C study

Heptares and Kymab collaborate on novel antibodies targeting GPCRs

Gilead's GS-9674 shows promise in treating nonalcoholic steatohepatitis

FDA approves Gilotrif for advanced squamous cell carcinoma of the lung

Boehringer Ingelheim exercises option to oncology target under Oxford BioTherapeutics collaboration

FDA issues complete response letter for Mycapssa in acromegaly

EMA committee extends safety review of direct-acting antivirals

Enrollment complete in Japanese phase I/II study of HGF gene therapy in primary lymphedema

Constellation Pharmaceuticals discovers novel EZH2 methyltransferase inhibitors

Infinity Pharmaceuticals develops PI3Kgamma inhibitors

Proximagen reports development of SSAO inhibitors

Flatley Discovery Lab patents CFTR channel correctors

Trinity College Dublin divulges compounds for multiple sclerosis

A*STAR reports antimicrobial imidazolium compounds

AC Immune and Biogen collaborate in neurodegenerative diseases

Vernalis' CCP-07 completes pivotal bioavailability study

ExxPharma Therapeutics and Halo Pharmaceutical announce collaboration

AmpliPhi terminates exclusive channel collaboration with Intrexon

WHO advisory group recommends use of Dengvaxia in endemic countries

FDA orphan drug status conferred on Debio-1143 for ovarian cancer

Armodafinil improves daytime somnolence and psychiatric features associated with DLB

Bioprojet Pharma's Wakix approved in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...